![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Health Plans Aim To Connect Costs of Hep C, Cancer Drugs to Patient Outcomes
Health Plans Aim To Connect Costs of Hep C, Cancer Drugs to Patient Outcomes
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/GreenDollarSign.gif?t=1433864063&width=430)
June 23, 2016
An analysis shows that a majority of health plans want to pursue outcomes-based contracts with specialty drugmakers.
Healthcare consulting firm Avalere Health surveyed 42 U.S. health plans and noted particular interest among health plans to tying product reimbursement to patient outcomes for Hepatitis C and oncology drugs.
Of the health plans surveyed, 63 percent indicated interest in outcomes-based reimbursement for Hepatitis C drugs. Fifty-three percent demonstrated interest in this reimbursement for oncology drugs.
Upcoming Events
-
21Oct